This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
Male or women of non-child bearing potential
BMI 18.0 to 35.0
Good overall health deemed by the study Investigator
CHB infection documented at least 12 months prior to screening
No history of cirrhosis of the liver
No current infections of Hepatitis A, D, and E, human immunodeficiency virus (type 1 and 2), and no history of or current hepatitis C. In addition, no other active infections deemed clinically relevant.
No signs of hepatocellular carcinoma
Not received an organ transplant